THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE
Celularity is fundamentally altering how we approach the treatment of Cancer, Infectious Diseases, and Degenerative Diseases through continuous, innovative application of new discoveries in cellular medicine.
BEST IN CLASS & SCALABLE
Cellular Medicine manufacturing
Featuring industry leading and diverse product lines
ALLOGENEIC PLATFORM
Built on two decades of science
Driven by a deep, seasoned management team
INNOVATIVE PLACENTA-DERIVED
T cells, NK Cells, and pluripotent stem cells
With greater expandability, persistence, and stem-ness
OUR MISSION
is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics
OUR VISION
Harness the Unique Biology & Ready Availability of the Placenta
- Unmet Global NeedSignificant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelf
- Groundbreaking ResearchGroundbreaking basic & translational research into the unique biological activity of placental-derived cells
- Pioneering TechnologyPioneering technology platform of placental-derived cellular medicines and advanced biomaterials
- Industry TimingThe time has arrived for cellular medicines that overcome barriers of scale, quality, and economics
Cellular Medicine Manufacturing
The Process is the Product
A fully integrated, purpose-built manufacturing, translational research and biobanking center
- Purpose built facility staffed by over 100 highly specialized scientists, engineers & technicians
- 150,000sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterials
- Clinical Scale – (9) Grade C/ISO 7 suites and (6) Grade D/ISO 8 labs ALL GMP-CAPABLE
The Latest From Our
NEWSROOM
Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval.
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021